Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials

BACKGROUND: Programmed death 1 protein (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are promising cancer immunotherapy. Their dermatologic safety profiles are still poorly understood. The purpose of this article is to evaluate the incidence of selected dermatologic and mucosal adverse eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wenwei, Li, Shuquan, Yang, Qingrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531085/
https://www.ncbi.nlm.nih.gov/pubmed/31096532
http://dx.doi.org/10.1097/MD.0000000000015731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531085/
https://www.ncbi.nlm.nih.gov/pubmed/31096532
http://dx.doi.org/10.1097/MD.0000000000015731

Ejemplares similares